Eltrombopag (Promacta, Revolade)
Indications
- Thrombocytopenia (see Thrombocytopenia, [[Thrombocytopenia]]): FDA-approved in 2008
- Refractory Aplastic Anemia (see Aplastic Anemia, [[Aplastic Anemia]]): FDA-approved for this indication in 2/14
- Thrombocytopenia Associated with Cirrhosis Due to Hepatitis C (see End-Stage Liver Disease, [[End-Stage Liver Disease]])
- Immune Thrombocytopenic Purpura (ITP) (see Immune Thrombocytopenic Purpura, [[Immune Thrombocytopenic Purpura]])
Pharmacology
- Small Molecule Agonist of Thrombopoetin Receptor (cMpl): increases platelet production
Administration
Adverse Effects
Cardiovascular Adverse Effects
- Orthostatic Hypotension (see Hypotension, [[Hypotension]])
Dermatologic Adverse Effects
- Alopecia (see Alopecia, [[Alopecia]])
- Pruritus (see Pruritus, [[Pruritus]])
- Rash
Hematologic Adverse Effects
- Bone Marrow Reticulin Deposition
- Hemorrhage
- Increased Risk of Hematologic Malignancy
- Thrombosis/Thromboembolism (see Hypercoagulable States, [[Hypercoagulable States]])
- Worsening Thrombocytopenia After Eltrombopag Discontinuation
Gastrointestinal/Hepatic Adverse Effects
- Abdominal Pain (see Abdominal Pain, [[Abdominal Pain]])
- Diarrhea (see Diarrhea, [[Diarrhea]])
- Hepatotoxicity/Hepatic Decompensation: when used in patients with hepatitis C
- Nausea/Vomiting (see Nausea and Vomiting, [[Nausea and Vomiting]])
Neurologic Adverse Effects
Otolaryngologic Adverse Effects
- Oropharyngeal Pain
- Rhinorrhea
- Upper Respiratory Infection
- Xerostomia
Rheumatologic Adverse Effects
Other Adverse Effects
- Cataracts (see Cataracts, [[Cataracts]])
- Cough (see Cough, [[Cough]])
- Fever (see Fever, [[Fever]])
References